Hengrui Pharmaceutical (01276): HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets approved for clinical trials

Zhitong Finance App News, Hengrui Pharmaceutical (01276) announced that recently, the company and its subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd., Shandong Shengdi Pharmaceutical Co., Ltd., and Chengdu Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue “Drug Clinical Trial Approval Notice” for HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets, and will conduct clinical trials in the near future.

It is reported that HRS-6208 is a novel, efficient, and selective small-molecule inhibitor that can effectively and selectively inhibit phosphorylation activation of targets, affect cell cycle and transcriptional activity, thereby inhibiting tumor cell proliferation and exhibiting anti-tumor effects. According to inquiries, there are currently no similar products approved for sale at home or abroad. Up to now, the total R&D investment for HRS6208 related projects is about 38.14 million yuan.

HRS-6209 is a novel selective CDK4 inhibitor that can strongly inhibit the CDK4/cyclind complex and downstream signals, induce tumor cells to block the G1 phase, and thereby exert an antitumor effect. It is clinically intended for the treatment of advanced malignant solid tumors. Compared with CDK4/6 inhibitors, selectivity for the CDK6/cyclind3 signaling pathway is improved, and blood toxicity associated with CDK4/6 inhibitors can be improved. According to inquiries, no similar products have been approved for sale at home or abroad. Up to now, the total R&D investment for HRS-6209 related projects is about 119.85 million yuan.

HRS-8080 tablets are a novel, highly effective, and selective oral estrogen receptor degrading agent (SERD). It can effectively and selectively degrade ER, inhibit ER activity and downstream signals, thereby inhibiting tumor cell proliferation. It is intended for the treatment of ER-positive and ER-mutated breast cancer. Up to now, the total R&D investment for HRS-8080 film-related projects is about 19.87 million yuan.

HRS-5041 is a novel, efficient, and selective AR PROTAC (androgen receptor-proteolytic target chimera) small molecule developed by the company and intended to treat prostate cancer. HRS-5041 has a significant degrading effect on wild-type AR proteins and most mutants, and has the potential to overcome drug resistance compared to second-generation AR inhibitors. According to inquiries, there are currently no similar products approved for listing at home or abroad. Up to now, HRS-5041 film-related projects have invested a total of about 92.66 million yuan in R&D expenses.

HRS-1358 is a novel, efficient, and selective PROTAC molecule independently developed by the company that targets estrogen receptor (ER) degradation. It can effectively and selectively degrade ER, inhibit ER transcriptional activity and downstream signals, thereby inhibiting tumor cell proliferation and exhibiting anti-tumor effects. Compared with traditional small molecule drugs, it can overcome target protein mutation resistance and is more selective for target proteins. No similar drug has been approved for marketing at home or abroad. Up to now, HRS-1358 film-related projects have invested a total of about 96.01 million yuan in R&D expenses.